Wedbush analyst Liana Moussatos maintained a Buy rating on Eiger Biopharmaceuticals (EIGR) today and set a price target of $35. The company’s shares opened today at $11.36.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.2% and a 32.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Eiger Biopharmaceuticals is a Moderate Buy with an average price target of $31.50, representing a 177.3% upside. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.19 million. In comparison, last year the company had a GAAP net loss of $8.83 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EIGR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.
